Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)

Hepatology

Volumn 64, Issue 2, 2016, Pages 360-369

  Lawitz, Eric ^a   Matusow, Gary ^b   DeJesus, Edwin ^c   Yoshida, Eric M ^d   Felizarta, Franco ^e   Ghalib, Reem ^f   Godofsky, Eliot ^g   Herring, Robert W ^h   Poleynard, Gary ⁱ   Sheikh, Aasim ^j   Tobias, Hillel ^k   Kugelmas, Marcelo ^l   Kalmeijer, Ronald ^m   Peeters, Monika ⁿ   Lenz, Oliver ⁿ   Fevery, Bart ⁿ   De La Rosa, Guy ^m   Scott, Jane ^o   Sinha, Rekha ^m   Witek, James ^m  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b The Gastroenterology Group of South Jersey   (United States)

^c ORLANDO IMMUNOLOGY CENTER   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Private Practice   (United States)

^f Texas Clinical Research Institute   (United States)

^g University Hepatitis Center at Pointe West Infectious Diseases   (United States)

^h Quality Medical Research   (United States)

ⁱ Digestive Health Specialists   (United States)

^j Gastrointestinal Specialists of Georgia   (United States)

^k The Concord Medical Group   (United States)

^l South Denver Gastroenterology PC   (United States)

^m JANSSEN RESEARCH AND DEVELOPMENT   (United States)

ⁿ JANSSEN RESEARCH FOUNDATION   (Belgium)

^o Janssen Global Services   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINOTRANSFERASE; AMYLASE; BILIRUBIN; SIMEPREVIR; SOFOSBUVIR; TRIACYLGLYCEROL LIPASE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALBUMIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BITE; CELLULITIS; CHRONIC HEPATITIS C; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERTRANSAMINASEMIA; LIMB INJURY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONCARDIAC CHEST PAIN; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; RECURRENCE RISK; SIDE EFFECT; TRAFFIC ACCIDENT; TREATMENT FAILURE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WOUND INFECTION;

EID: 84979066379     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28422     Document Type: Article

References (22)

1. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61:S58-S68.
2. Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol 2015;12:284-292.
3. European Association for the Study of the Liver. Clinical practice guidelines: recommendations on treatment of hepatitis C 2015. http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/recommendations-on-treatment-of-hepatitis-c-2015. Accessed May 5, 2015.
4. American Association for the Study of Liver Diseases. HCV guidance: recommendations for testing, managing, and treating hepatitis C. www.hcvguidelines.org/full-report-view. Accessed May 5, 2015.
5. Kleinman L, Mannix S, Yuan Y, Kummer S, L'Italien G, Revicki D. Review of patient-reported outcome measures in chronic hepatitis C. Health Qual Life Outcomes 2012;10:92.
6. Radloff LS. A self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
7. EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
8. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669-1679.
9. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
10. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. Simeprevir (TMC435) in treatment-experienced HCV genotype 1 patients; the phase IIb, randomized controlled ASPIRE trial. Gastroenterology 2014;146:430-441.
11. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-1765.
12. Pearlman BL, Ehleben C, Perrys M. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C–related Child's class A cirrhosis. Gastroenterology 2015;148:762-770.
13. Flamm S, Bacon B, Dieterich D, Kowdley K, Lawitz E, Milligan S, et al. Evaluation of efficacy of sofosbuvir and simeprevir-based regimens in a real-life population of HCV patients with cirrhosis; data from the TRIO network. Poster 983 presented at the American Association for the Study of Liver Disease (AASLD), Boston, MA, November 7-11, 2014.
14. Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Vargas HE, Galati JS, et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: report from HCV-TARGET. Oral presentation O007 presented at the European Association for the Study of the Liver, Vienna, Austria, April 22-26, 2015.
15. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
16. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
17. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-1982.
18. Olysio (simeprevir) US prescribing information. Titusville, NJ: Janssen Research & Development; October 2015. http://www.olysio.com/shared/product/olysio/prescribing-information.pdf.
19. European Medicines Agency. Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002777/WC500167867.pdf. Accessed May 27, 2015.
20. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalskiy VV, et al. Simeprevir (TMC435) with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-413.
21. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384:414-426.
22. Kwo P, Gitlin N, Nahass R, Bernstein B, Rojter S, Schiff E, et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1 [Abstract]. J Hepatol 2015;62(Suppl. 2):S270.